Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Merck Research Laboratories

Merck and Company

Rahway

NJ 07065

USA

Name/email consistency: high

Merck Research Laboratories, Merck and Company, Rahway, NJ 07065, USA. 2005
Department of Atherosclerosis and Endocrinology, Department of Molecular Endocrinology, Department of Genomic Pharmacology, Merck Research Laboratories, USA. 2000
Departments of Endocrinology and Chemical Biology and of Immunology and Rheumatology, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, USA. 1999

11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. Hermanowski-Vosatka, A., Balkovec, J.M., Cheng, K., Chen, H.Y., Hernandez, M., Koo, G.C., Le Grand, C.B., Li, Z., Metzger, J.M., Mundt, S.S., Noonan, H., Nunes, C.N., Olson, S.H., Pikounis, B., Ren, N., Robertson, N., Schaeffer, J.M., Shah, K., Springer, M.S., Strack, A.M., Strowski, M., Wu, K., Wu, T., Xiao, J., Zhang, B.B., Wright, S.D., Thieringer, R. J. Exp. Med. (2005) [Pubmed]
PPARalpha agonists reduce 11beta-hydroxysteroid dehydrogenase type 1 in the liver. Hermanowski-Vosatka, A., Gerhold, D., Mundt, S.S., Loving, V.A., Lu, M., Chen, Y., Elbrecht, A., Wu, M., Doebber, T., Kelly, L., Milot, D., Guo, Q., Wang, P.R., Ippolito, M., Chao, Y.S., Wright, S.D., Thieringer, R. Biochem. Biophys. Res. Commun. (2000) [Pubmed]
Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration. Hermanowski-Vosatka, A., Mundt, S.S., Ayala, J.M., Goyal, S., Hanlon, W.A., Czerwinski, R.M., Wright, S.D., Whitman, C.P. Biochemistry (1999) [Pubmed]